Start Your Search
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
EP1.01-84 - Second Line Treatment with Docetaxel/Nintedanib in Patients with Metastatic Non Small Cell Lung Adenocarcinoma-Preliminary Results (Now Available) (ID 2302)
08:00 - 18:00 | Author(s): Vasili Edvin
The treatment landscape of non small cell lung cancer (NSCLC) has changed dramatically during the last years involving targeted therapy, chemotherapy ± immunotherapy or/and antiangiogenic agents, based mainly on patients’ molecular characteristics. Not all patients respond well to immunotherapy, so there is an essential need for other effective treatments.Method
The aim of this prospective study is to estimate and record, the efficacy of the combination of Docetaxel with Nintedanib as a second line therapy in metastatic NSCLC. There were 20 patients, 16(80%) men, 4(20%) women, median age 62(52-73) years and median ECOG 1(0-3), without driver mutations, consecutively admitted in Evangelismos Oncology Department in Athens, Greece from 27/11/2017- 23/02/2019.Result
All patients had received Cisplatin/Pemetrexed/Bevacizumab as first line treatment for their disease, with a median duration of 104(45-255) days. Progressive disease sites were found in lung, liver, and bones in :18/20(90%), 8/20(40%) and 4/20(20%) patients respectively. All received as second line treatment Docetaxel 75mg/m2 q3weeks plus Nintedanib 400mg p.o., d 2-20 in 21 days cycles. CEA, CA125, NSE, CA19.9, CA72-4 and Cyfra 21.1 tumor markers were monitored according to our clinical protocol. Increased values of these markers were documented at initiation of therapy in 18, 14, 10, 14 ,0, 2 patients respectively.
After 3 cycles of treatment all patients were reevaluated and in 2 of them partial response (P.R.) was documented, with 40-50% reduction of CEA, CA125, CA19.9 και Cyfra 21.1, while 12 patients had stable disease (S.D.) with no more than 20% change in the aforementioned tumor markers. Six patients with progressive disease (P.D.) showed significant increase of CEA, CA 125, NSE, CA 19.9 and CA 72-4. The responders (P.R.+ S.D.) continued therapy for a median of 5(3-8) cycles.
Among 96 cycles of chemotherapy, any toxicity grade ≥ ΙΙ occurred in 14 (7%) of them. Anaemia in 7(50%), stomatitis in 4(28.5%), diarrhea in 5(36%) and AST/ALT elevation of >2.5 fold in 3(21%) cycles respectively. All patients were treated symptomatically, without dose reduction in any patientsConclusion
The combination of Docetaxel/Nintedanib in metastatic NSCLC adenocarcinoma, following progressive disease post Cisplatin/ Pemetrexed/ Bevacizumab treatment, showed 70% response rate. Although the number of the patients included in the study is small, we concluded that the tumor markers examined, had a clear correlation with the disease outcome. No major toxicity issues were documented. Larger studies are needed in order to make more solid conclusions.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.